Although four studies used ipragliflozin and one study used luseogliflozin, all studies demonstrated that SGLT2 inhibitors attenuated development of NAFLD or NASH [13–16]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.